✕
Tag:Also in the news Business Industries 2023-09-06 09:37
Nestlé has divested its peanut allergy treatment business, Palforzia, to biopharmaceutical company Stallergenes Greer.
Headquartered in Switzerland, Stallergenes Greer specialises in the diagnosis and treatment of respiratory allergies through immunotherapy.
The deal follows Nestlé’s announcement last year, stating its intention to undertake a strategic review of Palforzia. The food giant said it will “receive milestone payments and ongoing royalties” from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said: “We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world. At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers.”
According to the company, a customary transition period will be implemented to ensure business continuity and to provide patients with uninterrupted access to the treatment.
Terms of the transaction were not disclosed.
Why Chardonnay Is The Best Wine To Pair With Lobster Rolls
Don't Go To A Brazilian Steakhouse Without Knowing How To Use The Table Cards
The Chef-Approved Ingredient That Thickens Runny Takeout Sauces
Cured Vs Uncured Hot Dogs: What's The Difference Between The Sausages?
Even Grilled Chicken Can Be Fall-Themed With The Right Ingredients
Give Store-Bought Honey Mustard A Restaurant-Quality Kick With One Ingredient
About Us Terms of Service Privacy Policy Contact Us
Hotline(+86)17301604571
Enterprise WeChat
for Client Service
EZBuy
WeChat APP
Sinoexpo Digital Platform
Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. All rights reserved 沪ICP备05034851号-77 沪公网安备31010402000543号